Clicky

Basilea Pharmaceutica AG(BSLN)

Description: Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.


Keywords: Medicine Infectious Diseases Tumor Anti Infectives Staphylococcus Aureus Bacterial Disease Pyrrolidines Skin And Skin Structure Infections Basilea Pharmaceutica Stomach Cancer Bacteremia Hospital Acquired Pneumonia Invasive Aspergillosis Thiazoles Bile Duct Cancer Ceftobiprole Cresemba Invasive Fungal Infections Isavuconazonium Mucormycosis Thiadiazoles Zevtera

Home Page: www.basilea.com

Grenzacherstrasse 487
Basel, 4058
Switzerland
Phone: 41 61 606 11 11


Officers

Name Title
Mr. David Veitch Chief Exec. Officer
Mr. Adesh Kaul Chief Financial Officer
Dr. Gerrit Hauck Ph.D. Chief Technology Officer
Dr. Laurenz Kellenberger Ph.D. Chief Scientific Officer
Dr. Marc Engelhardt M.D. Chief Medical Officer
Dr. Peer Nils Schroder Head of Corp. Communications & Investor Relations
Mr. Damian Heller Gen. Counsel & Corp. Sec.
Ms. Ursula Eberhardt Head of Global HR
Mr. Lutz Wevelsiep Head of Regulatory Affairs
Mr. Dietrich Stüber Head of Internal Services

Exchange: SW

Country: CH

Currency: Swiss Franc (CHF)

Forward PE: 104.1667
Trailing PE: 222.6087
Price-to-Book MRQ: 0
Price-to-Sales TTM: 3.6918
IPO Date:
Fiscal Year End: December
Full Time Employees: 177
Back to stocks